on PolyPeptide Group
Samsung Biologics Concludes Tender for PolyPeptide Group
Samsung Biologics, through its subsidiary Samsung Peptide, has announced the definitive results of its tender offer for PolyPeptide Group’s shares. As of October 30, 2026, Samsung Peptide holds 97.99% of PolyPeptide's share capital and voting rights, with 97.66% of shares tendered within the acceptance period.
The offer's completion is pending regulatory approvals across various jurisdictions, with settlement anticipated by late 2026 or early 2027. Samsung Peptide aims to initiate a squeeze-out process for remaining shareholders and plans to delist PolyPeptide from the SIX Swiss Exchange post-settlement.
Further details are accessible on Samsung Biologics' website, marking a significant step in their strategic expansion within the biotech sector.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PolyPeptide Group news